Skip to content
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Genetics · ATTRv V30M Amyloidosis

Talk to Family About ATTRv V30M Genetic Testing

At a Glance

A certified genetic counselor should guide family genetic screening for ATTRv V30M amyloidosis. Biological children have a 50% chance of inheriting the mutation. Testing early allows for close monitoring and early use of therapies to halt the disease before severe symptoms develop.

Talking to your adult children about genetic testing for the ATTRv V30M mutation is one of the most emotionally challenging parts of managing hereditary amyloidosis. Because the condition is passed down through families, each biological child of a person with the V30M mutation has a 50% chance of inheriting it [1]. The best approach is to have an open, compassionate conversation, but it is highly recommended to use a certified genetic counselor to help guide this process [1]. A genetic counselor can explain the risks, address complex emotions, and help your children decide when and if they want to be tested.

Preparing for the Conversation

Before talking to your family, it is helpful to be prepared with clear information and emotional readiness. If you are struggling with how to start the conversation, consider a simple opening like: “My doctor recently found the specific genetic cause for my amyloidosis. Because it can be passed down in families, I want to share this information so you have the choice to talk to a professional about what it might mean for your own health.”

  • Educate yourself on the genetics: Understand that ATTRv is an autosomal dominant condition, meaning that a single copy of the mutated gene from one parent causes a 50% risk for each child [1].
  • Understand incomplete penetrance: It is important to reassure your children that inheriting the mutation does not guarantee they will develop the disease. This concept, called incomplete penetrance, means that some people with the gene mutation never show symptoms, or onset may be very late in life.
  • Emphasize the power of knowing: Explain that knowing their genetic status early is a powerful medical tool. Continuous monitoring allows doctors to start disease-modifying therapies (such as TTR stabilizers or gene-silencing agents) at the very first objective signs of the disease, effectively halting it before symptoms become severe [2][3].
  • Acknowledge the emotional weight: Finding out about a genetic risk is frightening. Asymptomatic carriers of the mutation often face anxiety, depression, and significant psychosocial stress [4]. Validating these fears is an important step in supporting your children.

The Role of a Genetic Counselor

A genetic counselor is a specialized healthcare professional who helps families navigate the complex medical and emotional aspects of genetic testing. You can usually find a certified counselor by asking your diagnosing neurologist or checking national genetics professional directories.

  • Facilitating Family Communication: They can help structure the conversation and provide clear, objective information to your children about the specific TTR variant [1][5].
  • Timing and Cost of Testing: For V30M ATTRv, disease onset can be categorized as early (before age 50) or late (after age 50) [6]. A counselor will help your children decide the best age to get tested based on your family’s specific history, and can help navigate whether health insurance will cover the cost of predictive testing.
  • Family Planning Options: For adult children planning families, a genetic counselor can discuss options like preimplantation genetic diagnosis (PGD), a technique that can prevent the V30M mutation from being passed to future generations [7].

Addressing Fears: Insurance and Discrimination

A major fear for many families is whether a positive genetic test will negatively impact their ability to secure certain types of insurance. It is vital to understand the legal protections currently in place, particularly in the United States. (Note: International readers should research their own country’s genetic privacy and insurance laws, as legal protections vary widely.)

  • The Genetic Information Nondiscrimination Act (GINA): GINA is a US federal law that makes it illegal for health insurance companies or employers to discriminate against someone based on their genetic test results [8][9].
  • What GINA Does NOT Cover: GINA’s protections do not apply to life insurance, disability insurance, or long-term care insurance [8][10]. Because of this gap in the law, people with a known genetic risk for ATTRv may face discrimination or higher premiums when applying for these policies [11][12].
  • A Strategic Approach: Because public awareness of these rules is often low [13][14], discussing this clearly with your children is incredibly important. Many genetic counselors advise individuals to secure their life, disability, and long-term care insurance before undergoing predictive genetic testing [11].

Long-Term Monitoring and Psychological Support

If a child tests positive for the V30M mutation, it does not mean they are currently sick—they are considered an asymptomatic carrier.

  • Cascade Screening and Monitoring: Carriers undergo periodic multi-specialty evaluations, including neurological and cardiac assessments, to check for the earliest signs of the disease [15][16]. Doctors may also track blood biomarkers to monitor for silent progression, such as neurofilament light chain (sNfL) (which checks for early signs of nerve damage) and high-sensitivity cardiac troponin (which checks for early signs of heart strain) [17][18].
  • Emotional Support: Hereditary amyloidosis is a progressive disorder that impacts the whole family’s mental health and quality of life [19][20]. Clinical care for families facing this disease should always include resources focused on maintaining mental well-being alongside physical health [21][20]. Encourage your children to seek out psychological support or connect with specialized patient advocacy groups, such as the Amyloidosis Research Consortium or the Amyloidosis Foundation, which provide communities tailored for asymptomatic carriers.

Common questions in this guide

What are the chances of passing the ATTRv V30M mutation to my children?
ATTRv V30M amyloidosis is an autosomal dominant condition. This means that each biological child of a person with the mutation has a 50 percent chance of inheriting it.
Will my child definitely get sick if they inherit the ATTRv V30M mutation?
No, inheriting the mutation does not guarantee they will develop the disease. Due to a concept called incomplete penetrance, some carriers never show symptoms, or the onset may be very late in life.
Why should someone get tested for ATTRv V30M before they have symptoms?
Knowing their genetic status allows asymptomatic carriers to be closely monitored. Doctors can start disease-modifying therapies at the very first objective signs of the disease, effectively halting it before severe symptoms develop.
Will a positive genetic test affect my child's ability to get insurance?
In the US, the GINA law protects against health insurance and employment discrimination based on genetics. However, it does not cover life, disability, or long-term care insurance, so it is often advised to secure these policies before testing.
How are asymptomatic carriers of the V30M mutation monitored?
Carriers undergo periodic neurological and cardiac evaluations to check for early signs of the disease. Doctors also track specific blood biomarkers, like neurofilament light chain and high-sensitivity cardiac troponin, to detect silent progression.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you refer my family to a certified genetic counselor who has specific experience with ATTRv amyloidosis?
  2. 2.At what age do you recommend my adult children undergo genetic testing, given the specific onset age of my V30M mutation?
  3. 3.If my child tests positive but has no symptoms, what specific biomarkers and imaging will be used to monitor them, and how often?
  4. 4.Are there local or virtual support groups specifically tailored for families and asymptomatic carriers of hereditary amyloidosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Counseling Family Members and Monitoring for Evidence of Disease in Asymptomatic Carriers of Amyloid Transthyretin Cardiac Amyloidosis.

    Barker N, Judge DP

    The American journal of cardiology 2022; (185 Suppl 1()):S43-S50 doi:10.1016/j.amjcard.2022.09.011.

    PMID: 36216601
  2. 2

    Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness.

    Nativi-Nicolau JN, Karam C, Khella S, Maurer MS

    Heart failure reviews 2022; (27(3)):785-793 doi:10.1007/s10741-021-10080-2.

    PMID: 33609196
  3. 3

    Transthyretin: Its function and amyloid formation.

    Ueda M

    Neurochemistry international 2022; (155()):105313 doi:10.1016/j.neuint.2022.105313.

    PMID: 35218869
  4. 4

    Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study.

    Inês M, Coelho T, Conceição I, et al.

    Orphanet journal of rare diseases 2020; (15(1)):67 doi:10.1186/s13023-020-1340-x.

    PMID: 32143656
  5. 5

    Hereditary ATTR amyloidosis: a single-institution experience with 266 patients.

    Swiecicki PL, Zhen DB, Mauermann ML, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2015; (22(2)):123-31 doi:10.3109/13506129.2015.1019610.

    PMID: 26017327
  6. 6

    Response: Suhr OB: commentary to Isabel Conceição et al. early diagnosis through targeted follow-up of identified carriers of TTR gene mutations.

    Conceição I

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2019; (26(4)):248-249 doi:10.1080/13506129.2019.1642191.

    PMID: 31364873
  7. 7

    Clinical outcomes after preimplantation genetic diagnosis of patients with Corino de Andrade disease (familial amyloid polyneuropathy).

    Lopes R, Sousa M, Silva J, et al.

    Reproductive biomedicine online 2018; (36(1)):39-46 doi:10.1016/j.rbmo.2017.09.010.

    PMID: 29079197
  8. 8

    Prohibiting Genetic Discrimination to Promote Science, Health, and Fairness.

    American journal of human genetics 2019; (104(1)):6-7 doi:10.1016/j.ajhg.2018.12.005.

    PMID: 30609408
  9. 9

    GINA at 10 years: the battle over 'genetic information' continues in court.

    Suter SM

    Journal of law and the biosciences 2018; (5(3)):495-526 doi:10.1093/jlb/lsz002.

    PMID: 31143453
  10. 10

    Beyond the Genetic Information Nondiscrimination Act: ethical and economic implications of the exclusion of disability, long-term care and life insurance.

    Tenenbaum JD, Goodman KW

    Personalized medicine 2017; (14(2)):153-157 doi:10.2217/pme-2016-0078.

    PMID: 29754558
  11. 11

    Banning Genetic Discrimination in Life Insurance - Time to Follow Florida's Lead.

    Rothstein MA, Brothers KB

    The New England journal of medicine 2020; (383(22)):2099-2101 doi:10.1056/NEJMp2024123.

    PMID: 33253510
  12. 12

    Legal Challenges in Genetics, Including Duty to Warn and Genetic Discrimination.

    Suter S

    Cold Spring Harbor perspectives in medicine 2020; (10(4)) doi:10.1101/cshperspect.a036665.

    PMID: 31548231
  13. 13

    The Genetic Information Nondiscrimination Act and workplace genetic testing: Knowledge and perceptions of employed adults in the United States.

    Willard L, Uhlmann W, Prince AER, et al.

    Journal of genetic counseling 2025; (34(2)):e1945 doi:10.1002/jgc4.1945.

    PMID: 39037108
  14. 14

    The persistent lack of knowledge and misunderstanding of the Genetic Information Nondiscrimination Act (GINA) more than a decade after passage.

    Lenartz A, Scherer AM, Uhlmann WR, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(12)):2324-2334 doi:10.1038/s41436-021-01268-w.

    PMID: 34400812
  15. 15

    Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers.

    Beauvais D, Labeyrie C, Cauquil C, et al.

    Journal of neurology, neurosurgery, and psychiatry 2024; (95(6)):489-499 doi:10.1136/jnnp-2023-332180.

    PMID: 37875336
  16. 16

    Diagnosis and Management of Mixed Phenotype Hereditary Transthyretin Amyloidosis: A Case-Based, Canadian Perspective.

    Fine N, Ducharme A, Matte G, et al.

    CJC open 2025; (7(5)):614-627 doi:10.1016/j.cjco.2025.03.002.

    PMID: 40433205
  17. 17

    Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.

    Berends M, Brunger AF, Bijzet J, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2024; (31(2)):132-141 doi:10.1080/13506129.2024.2327342.

    PMID: 38477065
  18. 18

    High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis Patients.

    Tingen HSA, Berends M, Tubben A, et al.

    Journal of clinical medicine 2024; (13(3)) doi:10.3390/jcm13030810.

    PMID: 38337504
  19. 19

    Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers.

    Stewart M, Shaffer S, Murphy B, et al.

    Neurology and therapy 2018; (7(2)):349-364 doi:10.1007/s40120-018-0106-z.

    PMID: 30073497
  20. 20

    Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis.

    Aimo A, Rapezzi C, Perfetto F, et al.

    European journal of clinical investigation 2021; (51(11)):e13598 doi:10.1111/eci.13598.

    PMID: 33982288
  21. 21

    Care of Patients With Transthyretin Amyloidosis: the Roles of Nutrition, Supplements, Exercise, and Mental Health.

    Dasgupta NR

    The American journal of cardiology 2022; (185 Suppl 1()):S35-S42 doi:10.1016/j.amjcard.2022.10.053.

    PMID: 36549789

This page provides general guidance on family genetic screening for ATTRv V30M amyloidosis for informational purposes only. Always consult a certified genetic counselor or physician regarding specific genetic testing, family planning decisions, and medical monitoring.

Get notified when new evidence is published on ATTRV30M amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.